Skip to main content
Top

Open Access 09-06-2025 | Rheumatoid Arthritis | ORIGINAL ARTICLE

Computed tomography-based quantitative scoring system for rheumatoid arthritis–associated interstitial lung disease: a retrospective diagnostic accuracy study for progressive fibrosis detection

Authors: Mehmet Cihan Karacaoğlu, Betül Kızıldağ, Burak Okyar, Gözde Yıldırım Çetin, Adem Doğaner, Nurhan Atilla

Published in: Clinical Rheumatology

Login to get access

Abstract

Objectives

To investigate the ability of quantitative parameters to assess the severity of rheumatoid arthritis (RA)–associated interstitial lung disease (ILD).

Methods

Thorax CT images and pulmonary function tests of RA patients followed up in a tertiary reference center were retrospectively examined. Radiologically, patients were divided into two groups as limited and extensive ILD, using two semiquantitative scoring systems. Two different methods (Method 1, Method 2) were used for quantitative image analysis, in which different Hounsfield unit values were selected as thresholds. Spearman’s correlation test was used to evaluate the relationship between variables. The diagnostic performance of quantitative methods for the ability to distinguish limited ILD from extensive ILD was calculated using ROC analysis.

Results

Forty-four patients, 29 female and 15 male, were included in the study. A significant correlation was found between diffusion capacity of the lungs carbonmonoxide (DLCO) and total lung capacity (TLC), which are clinical markers, and both quantitative methods (p < 0.001). In terms of the performance of diagnostic tests, the power of Method 1 and Method 2 to distinguish limited and extensive disease classified based on semiquantitative scores was found to be strong (Method 1 AUC = 0.945, Method 2 AUC = 0.785 based on “ILD score”; Method 1 AUC = 0.911, Method 2 AUC = 0.700 based on “modified coarseness of reticular disease (MCRD) score”).

Conclusion

This study demonstrates that quantitative methods (Method 1 [− 700 to − 200 HU] and Method 2 [− 800 to − 500 HU]) play a significant role in assessing the severity of RA-associated ILD (RA-ILD). Both methods showed significant correlations with pulmonary function tests (DLCO [r1 = − 0.338, p1 = 0.025; r2 = − 0.452, p2 = 0.002] and TLC [r1 = − 0.567, p1 < 0.001; r2 = − 0.576, p2 < 0.001), with Method 1 (AUCILD = 0.945 and AUCMCRD = 0.911) demonstrating superior performance in distinguishing between limited and extensive ILD. Our findings suggest that Hounsfield unit threshold–based quantitative CT analysis may serve as a more objective and reproducible alternative to semiquantitative systems (e.g., Goh score) in the standard evaluation of RA-ILD. Specifically, Method 1 may enable early detection of progression by mechanism, e.g., “tracking subtle density changes.” However, further validation in multicenter prospective cohorts is needed to address limitations such as bias.
Key Points
Interobserver and intraobserver variability poses a significant challenge in the objective assessment of rheumatoid arthritis–associated interstitial lung disease.
User independent quantitative methods can be used instead of user-dependent semiquantitative methods in assessing rheumatoid arthritis–associated interstitial lung disease.
Quantitative computed tomography analysis enables precise stratification of disease severity in rheumatoid arthritis-associated interstitial lung disease, distinguishing limited interstitial lung disease from extensive interstitial lung disease, which has a poor prognosis.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Computed tomography-based quantitative scoring system for rheumatoid arthritis–associated interstitial lung disease: a retrospective diagnostic accuracy study for progressive fibrosis detection
Authors
Mehmet Cihan Karacaoğlu
Betül Kızıldağ
Burak Okyar
Gözde Yıldırım Çetin
Adem Doğaner
Nurhan Atilla
Publication date
09-06-2025
Publisher
Springer International Publishing
Published in
Clinical Rheumatology
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-025-07511-y

Innovations in AML: insights and practical guidance

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME
Learn more

ADA 2025

Unlock your free and exclusive access to the latest news from the American Diabetes Association’s 85th Scientific Sessions.

Read more